博安生物港交所公告,公司自主开发的博优平®已获得国家药品监督管理局的上市批准,用于成人2型糖尿病患者的血糖控制。博优平®是一种长效GLP-1受体激动剂,其在中国大陆的商业化由公司与上药控股合作开展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.